ReviewBME frontiers2025
Sustainable Nanotechnology and Artificial Intelligence to Empower Image-Guided Therapy for Precision Healthcare.
Review in BME frontiers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Artificial intelligence driven protein design and sustainable nanomedicine for advanced theranostics.Bioactive materials · 2026Review
- Application of multimodal nanotechnology and standardized nursing management in ventricular arrhythmia.Biomedical engineering online · 2026Review
- Artificial Intelligence for Osteoporosis Diagnosis, Risk Prediction and Therapy: Current Advances, Clinical Challenges, and Future Perspectives.Clinical interventions in aging · 2026Review
- Advances in nanotechnology for early cancer diagnosis: emerging nanoplatforms and multimodal imaging approaches.American journal of cancer research · 2026Review
- Bioengineering Strategies to Address Key Bottlenecks in Ferroptosis-Based Cancer Therapy: A Critical Review.International journal of nanomedicine · 2026Review
- AI-engineered multifunctional nanoplatforms: synergistically bridging precision diagnosis and intelligent therapy in next-generation oncology.Journal of nanobiotechnology · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanotechnology has substantially advanced imaging, therapy, and clinical techniques, playing a crucial role in the development of sustainable functional materials in biomedical engineering. Nanoparticles, used as contrast agents in multimodal imaging, offer notable advantages due to their high surface area-to-volume ratio, enabling functionalization with targeting ligands for improved specificity and sensitivity. They can also carry multiple imaging agents or therapeutic drugs, promoting theranostics, an approach combining diagnosis and treatment. However, the need for high-dose contrast agents raises concerns about nanoparticle toxicity. Green nanotechnology addresses this by developing sustainable nanoparticles through eco-friendly synthesis methods, reducing environmental and health risks. Moreover, by using this method, safer imaging agents that align with current health standards can be generated. In parallel, recent advancements in artificial intelligence (AI) are transforming imaging applications. Beyond simple automation of image interpretation, AI is enhancing image acquisition, management, and interpretation, signaling a future where intelligent systems play a key role in healthcare. This review explores the diverse nanomaterials utilized as contrast agents in multimodal imaging, highlights the importance of green nanotechnology in minimizing toxicity, and emphasizes on the important role of AI in imaging and image-guided therapy. Together, these innovations are advancing precision healthcare, promising a future where diagnostics and treatment are not only more effective but also sustainable.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.